Atossa Therapeutics Awarded U.S. Patent, Including 58 Claims Covering Various Formulations For Its (Z)-Endoxifen Portfolio

Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced that the United States Patent and Trademark Office (USPTO) has granted a new patent (U.S. Patent No. 12,281,056) directed to highly pure and stable enteric oral formulations comprising (Z)-endoxifen as well as therapeutic methods of using those oral formulations.

The newly granted patent includes 58 claims covering (Z)-endoxifen formulations, including various levels of purity and stability as well as methods of using those formulations. This patent provides additional support for Atossa's intellectual property portfolio surrounding its proprietary (Z)-endoxifen formulations, a potent Selective Estrogen Receptor Modulator (SERM).

"The issuance of U.S. Patent No. 12,281,056 further showcases the work of our team of innovative researchers and our commitment to protecting our intellectual property, which will enhance and accelerate our mission of advancing the treatment of breast cancer," said Steven Quay, M.D., Ph.D., Atossa's President and Chief Executive Officer. "At Atossa, we are dedicated transforming the paradigm in breast cancer treatment, and we are confident that through this mission, we can greatly improve lives of millions of women who face breast cancer, while generating substantial value for our shareholders."

Atossa continues to add to its robust patent estate, which includes multiple U.S. patents, collectively encompassing over 200 patent claims related to (Z)-endoxifen formulations and their clinical applications. This comprehensive and ongoing protection strategy bolsters the company's continued leadership in developing targeted therapies for hormone receptor-positive breast cancer.​